Panacea Life Sciences Holdings, Inc.
PLSH
$0.07
-$0.05-40.12%
OTC PK
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 5.91% | 12.33% | 21.17% | 18.85% | -2.73% |
| Total Depreciation and Amortization | -3.23% | -1.05% | 1.01% | 3.56% | 0.66% |
| Total Amortization of Deferred Charges | -100.00% | -96.41% | -76.95% | -21.63% | 121.19% |
| Total Other Non-Cash Items | -5.67% | -28.42% | -49.74% | -34.33% | 61.27% |
| Change in Net Operating Assets | 72.44% | 94.32% | 58.56% | 22.81% | 32.57% |
| Cash from Operations | 31.17% | 36.47% | 34.04% | 35.47% | 36.08% |
| Capital Expenditure | 77.90% | 73.22% | -7.90% | -4,500.00% | -190.56% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -100.00% | -100.00% | -79.68% |
| Cash from Investing | 72.78% | 66.84% | -65.01% | -188.65% | -133.75% |
| Total Debt Issued | -54.01% | -51.87% | -9.04% | 10.00% | 30.17% |
| Total Debt Repaid | 83.42% | 76.87% | -98.42% | -138.90% | -431.06% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -33.64% | -34.83% | -32.87% | -18.67% | -14.54% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 98.84% | 834.38% | -257.85% | 70.06% | 141.79% |